Cargando…

The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy

Background and Objectives: Chemotherapy-induced febrile neutropenia is the most widespread oncologic emergency with high morbidity and mortality rates. Herein we present a retrospective risk factor identification study to evaluate the prognostic role of lymphocyte-based measures and ratios in a coho...

Descripción completa

Detalles Bibliográficos
Autores principales: Halalsheh, Omar M., Al Zu’bi, Yazan O., Al Sharie, Ahmed H., Wafai, Farouk H., Alabdallah, Nadeem, AlSeidi, Jumana, Hussein, Alia A., Daoud, Majd N., Malkawi, Abubaker A., Alomari, Ahmad O., Alshari, Osama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695543/
https://www.ncbi.nlm.nih.gov/pubmed/36363465
http://dx.doi.org/10.3390/medicina58111508
_version_ 1784838087265746944
author Halalsheh, Omar M.
Al Zu’bi, Yazan O.
Al Sharie, Ahmed H.
Wafai, Farouk H.
Alabdallah, Nadeem
AlSeidi, Jumana
Hussein, Alia A.
Daoud, Majd N.
Malkawi, Abubaker A.
Alomari, Ahmad O.
Alshari, Osama
author_facet Halalsheh, Omar M.
Al Zu’bi, Yazan O.
Al Sharie, Ahmed H.
Wafai, Farouk H.
Alabdallah, Nadeem
AlSeidi, Jumana
Hussein, Alia A.
Daoud, Majd N.
Malkawi, Abubaker A.
Alomari, Ahmad O.
Alshari, Osama
author_sort Halalsheh, Omar M.
collection PubMed
description Background and Objectives: Chemotherapy-induced febrile neutropenia is the most widespread oncologic emergency with high morbidity and mortality rates. Herein we present a retrospective risk factor identification study to evaluate the prognostic role of lymphocyte-based measures and ratios in a cohort of chemotherapy-induced febrile neutropenia patients following granulocyte colony-stimulating factor (G-CSF) therapy. Materials and Methods: The electronic medical records at our center were utilized to identify patients with a first attack of chemotherapy-induced febrile neutropenia and were treated accordingly with G-CSF between January 2010 to December 2020. Patients’ demographics and disease characteristics along with laboratory tests data were extracted. Prognosis-related indicators were the absolute neutrophil count (ANC) at admission and the following 6 days besides the length of stay and mortality rate. Results: A total of 80 patients were enrolled, which were divided according to the absolute lymphocyte count at admission into two groups, the first includes lymphopenia patients (n = 55) and the other is the non-lymphopenia group (n = 25) with a cutoff point of 700 lymphocytes/μL. Demographics and baseline characteristics were generally insignificant among the two groups but the white blood cell count was higher in the non-lymphopenia group. ANC, neutrophils percentage and ANC difference in reference to admission among the two study groups were totally insignificant. The same insignificant pattern was observed in the length of stay and the mortality rate. Univariate analysis utilizing the ANC difference compared to the admission day as the dependent variable, revealed no predictability role in the first three days of follow up for any of the variables included. However, during the fourth day of follow up, both WBC (OR = 0.261; 95% CI: 0.075, 0.908; p = 0.035) and lymphocyte percentage (OR = 1.074; 95% CI: 1.012, 1.141; p = 0.019) were marginally significant, in which increasing WBC was associated with a reduction in the likelihood of ANC count increase, compared to the lymphocyte percentage which exhibited an increase in the likelihood. In comparison, sequential ANC difference models demonstrated lymphocyte percentage (OR = 0.961; 95% CI: 0.932, 0.991; p = 0.011) and monocyte-to-lymphocyte ratio (OR = 7.436; 95% CI: 1.024, 54.020; p = 0.047) reduction and increment in the enhancement of ANC levels, respectively. The fifth day had WBC (OR = 0.790; 95% CI: 0.675, 0.925; p = 0.003) to be significantly decreasing the likelihood of ANC increment. Conclusions: we were unable to determine any concrete prognostic role of lymphocyte-related measures and ratios. It is plausible that several limitations could have influenced the results obtained, but as far as our analysis is concerned ALC role as a predictive factor for ANC changes remains questionable.
format Online
Article
Text
id pubmed-9695543
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96955432022-11-26 The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy Halalsheh, Omar M. Al Zu’bi, Yazan O. Al Sharie, Ahmed H. Wafai, Farouk H. Alabdallah, Nadeem AlSeidi, Jumana Hussein, Alia A. Daoud, Majd N. Malkawi, Abubaker A. Alomari, Ahmad O. Alshari, Osama Medicina (Kaunas) Article Background and Objectives: Chemotherapy-induced febrile neutropenia is the most widespread oncologic emergency with high morbidity and mortality rates. Herein we present a retrospective risk factor identification study to evaluate the prognostic role of lymphocyte-based measures and ratios in a cohort of chemotherapy-induced febrile neutropenia patients following granulocyte colony-stimulating factor (G-CSF) therapy. Materials and Methods: The electronic medical records at our center were utilized to identify patients with a first attack of chemotherapy-induced febrile neutropenia and were treated accordingly with G-CSF between January 2010 to December 2020. Patients’ demographics and disease characteristics along with laboratory tests data were extracted. Prognosis-related indicators were the absolute neutrophil count (ANC) at admission and the following 6 days besides the length of stay and mortality rate. Results: A total of 80 patients were enrolled, which were divided according to the absolute lymphocyte count at admission into two groups, the first includes lymphopenia patients (n = 55) and the other is the non-lymphopenia group (n = 25) with a cutoff point of 700 lymphocytes/μL. Demographics and baseline characteristics were generally insignificant among the two groups but the white blood cell count was higher in the non-lymphopenia group. ANC, neutrophils percentage and ANC difference in reference to admission among the two study groups were totally insignificant. The same insignificant pattern was observed in the length of stay and the mortality rate. Univariate analysis utilizing the ANC difference compared to the admission day as the dependent variable, revealed no predictability role in the first three days of follow up for any of the variables included. However, during the fourth day of follow up, both WBC (OR = 0.261; 95% CI: 0.075, 0.908; p = 0.035) and lymphocyte percentage (OR = 1.074; 95% CI: 1.012, 1.141; p = 0.019) were marginally significant, in which increasing WBC was associated with a reduction in the likelihood of ANC count increase, compared to the lymphocyte percentage which exhibited an increase in the likelihood. In comparison, sequential ANC difference models demonstrated lymphocyte percentage (OR = 0.961; 95% CI: 0.932, 0.991; p = 0.011) and monocyte-to-lymphocyte ratio (OR = 7.436; 95% CI: 1.024, 54.020; p = 0.047) reduction and increment in the enhancement of ANC levels, respectively. The fifth day had WBC (OR = 0.790; 95% CI: 0.675, 0.925; p = 0.003) to be significantly decreasing the likelihood of ANC increment. Conclusions: we were unable to determine any concrete prognostic role of lymphocyte-related measures and ratios. It is plausible that several limitations could have influenced the results obtained, but as far as our analysis is concerned ALC role as a predictive factor for ANC changes remains questionable. MDPI 2022-10-24 /pmc/articles/PMC9695543/ /pubmed/36363465 http://dx.doi.org/10.3390/medicina58111508 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Halalsheh, Omar M.
Al Zu’bi, Yazan O.
Al Sharie, Ahmed H.
Wafai, Farouk H.
Alabdallah, Nadeem
AlSeidi, Jumana
Hussein, Alia A.
Daoud, Majd N.
Malkawi, Abubaker A.
Alomari, Ahmad O.
Alshari, Osama
The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy
title The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy
title_full The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy
title_fullStr The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy
title_full_unstemmed The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy
title_short The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy
title_sort prognostic utility of lymphocyte-based measures and ratios in chemotherapy-induced febrile neutropenia patients following granulocyte colony-stimulating factor therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695543/
https://www.ncbi.nlm.nih.gov/pubmed/36363465
http://dx.doi.org/10.3390/medicina58111508
work_keys_str_mv AT halalshehomarm theprognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT alzubiyazano theprognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT alsharieahmedh theprognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT wafaifaroukh theprognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT alabdallahnadeem theprognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT alseidijumana theprognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT husseinaliaa theprognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT daoudmajdn theprognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT malkawiabubakera theprognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT alomariahmado theprognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT alshariosama theprognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT halalshehomarm prognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT alzubiyazano prognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT alsharieahmedh prognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT wafaifaroukh prognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT alabdallahnadeem prognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT alseidijumana prognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT husseinaliaa prognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT daoudmajdn prognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT malkawiabubakera prognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT alomariahmado prognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy
AT alshariosama prognosticutilityoflymphocytebasedmeasuresandratiosinchemotherapyinducedfebrileneutropeniapatientsfollowinggranulocytecolonystimulatingfactortherapy